Biomarker ID | 1733 |
PMID | 30866497 |
Year | 2019 |
Biomarker | Methylation Status of cg12799885 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed [Log Fold Change: EMX2OS: (-5.98142); LINC02137 (-5.28623); LINC01116 (-3.59594); LINC00839: (- 4.30616); AL161645.1: (-4.9543); AC012123.1: (-4.63826); AL354793.1 (-5.45876); LINC02385: (-5.3465); HOXBâ€AS3 (-5.22943); AC005674.1: (-3.98991);] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs No Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 197 patients with Prostate cancer along with 37 normal samples (27 adjacent normal and 9 Benign Prostatic Hyperplasia) samples are chosen for the study |
Senstivity | 73.2 % |
Specificity | 94.6% |
AUC | 0.8758 |
Accuracy | NA |
Level Of Significance | p < 0.001 |
Method Used | quantitative methylation specific PCR (qMSP) |
Clinical | No |
Remarks | Specificity fixed at 94.6%. Calculated sensitivity accordinly |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |